Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
98.22
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
101
Open
98.22
Bid (Size)
73.50 (1)
Ask (Size)
118.40 (3)
Prev. Close
98.22
Today's Range
98.22 - 98.22
52wk Range
64.11 - 105.00
Shares Outstanding
47,190,970
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
November 27, 2024
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.
Via
Benzinga
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
November 26, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+27.46%
+27.46%
1 Month
+10.56%
+10.56%
3 Month
+9.56%
+9.56%
6 Month
+31.42%
+31.42%
1 Year
+45.66%
+45.66%
More News
Read More
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
November 12, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
November 12, 2024
Via
Benzinga
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
October 04, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
September 09, 2024
Via
Benzinga
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
November 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
October 29, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
October 19, 2024
Via
The Motley Fool
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
October 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Unveiling 14 Analyst Insights On Axsome Therapeutics
August 22, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
August 05, 2024
Via
Benzinga
1 Under-the-Radar Biotech Stock to Buy and Hold
September 29, 2024
Via
The Motley Fool
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
September 24, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
September 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Investor Conferences in September
August 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
August 21, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
Via
PressReach
Exposures
Product Safety
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
August 06, 2024
Via
Benzinga
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
August 05, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Axsome Therapeutics Stock Is Sinking Today
August 05, 2024
Via
The Motley Fool
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
August 05, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
